Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Intestinal2466 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49108 | 17374528 | Clin Chim Acta | Non-invasive assessment of chronic liver and gastric diseases. | 2007 | Details |
| A49117 | 17058987 | Rev Gastroenterol Mex | [Ghrelin: beyond hunger regulation]. | 2006 | Details |
| A49156 | 16097995 | Aliment Pharmacol Ther | Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. | 2005 | Details |
| A49208 | 35822119 | JGH Open | Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. | 2022 | Details |
| A49209 | 35822025 | Front Aging | INDY-From Flies to Worms, Mice, Rats, Non-Human Primates, and Humans. | 2021 | Details |
| A49233 | 35814507 | J Clin Exp Hepatol | Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study. | 2022 | Details |
| A49234 | 35813333 | Ann Transl Med | Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via modulation of the gut-liver axis in mice. | 2022 | Details |
| A49257 | 35807929 | Nutrients | GOS Ameliorates Nonalcoholic Fatty Liver Disease Induced by High Fat and High Sugar Diet through Lipid Metabolism and Intestinal Microbes. | 2022 | Details |
| A49265 | 35806447 | Int J Mol Sci | New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49270 | 35806156 | Int J Mol Sci | The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs. | 2022 | Details |
| A49300 | 35795340 | Nanotheranostics | Emerging Role of Edible Exosomes-Like Nanoparticles (ELNs) as Hepatoprotective Agents. | 2022 | Details |
| A49301 | 35795290 | Evid Based Complement Alternat Med | Cannabis Extract Effects on Metabolic Parameters and Gut Microbiota Composition in a Mice Model of NAFLD and Obesity. | 2022 | Details |
| A49308 | 35792869 | FASEB J | Intestinal aberrant sphingolipid metabolism shaped-gut microbiome and bile acids metabolome in the development of hepatic steatosis. | 2022 | Details |
| A49338 | 35784533 | Front Endocrinol (Lausanne) | Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis. | 2022 | Details |
| A49344 | 35782947 | Front Nutr | Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis. | 2022 | Details |
| A49364 | 35777915 | J Adv Res | Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug. | 2021 | Details |
| A49405 | 35761655 | Food Res Int | Pueraria lobata starch regulates gut microbiota and alleviates high-fat high-cholesterol diet induced non-alcoholic fatty liver disease in mice. | 2022 | Details |
| A49415 | 35758365 | Medicine (Baltimore) | CONSORT-Characteristics and metabolic phenotype of gut microbiota in NAFLD patients. | 2022 | Details |
| A49426 | 35753609 | J Ethnopharmacol | Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis. | 2022 | Details |
| A49429 | 35752255 | J Control Release | Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis. | 2022 | Details |
| A49492 | 35738255 | Semin Liver Dis | Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. | 2022 | Details |
| A49498 | 35736186 | Mar Drugs | Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49524 | 35726797 | Food Funct | Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. | 2022 | Details |
| A49530 | 35724509 | Biomed Pharmacother | Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics. | 2022 | Details |
| A49541 | 35721143 | Front Pharmacol | Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice. | 2022 | Details |
| A49552 | 35717780 | Biomed Pharmacother | Postbiotics as potential new therapeutic agents for metabolic disorders management. | 2022 | Details |
| A49573 | 35709776 | Acta Gastroenterol Belg | Validation of Baveno VI and Expanded-Baveno VI Criteria for predicting gastroesophageal varices in patients with alcoholic and non-alcoholic fatty liver disease. | 2022 | Details |
| A49586 | 35702844 | J Assoc Physicians India | A Study on FibroScan and Endoscopic Finding in Patients of Chronic Liver Disease attending Tripura Medical College and Dr. B.R. Ambedkar Memorial Teaching Hospital. | 2022 | Details |
| A49595 | 35697165 | Int J Biol Macromol | Extraction, purification, structural characterization, and gut microbiota relationship of polysaccharides: A review. | 2022 | Details |
| A49601 | 35694542 | Front Cell Infect Microbiol | The Microbiota and It's Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49614 | 35691078 | Phytomedicine | The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis. | 2022 | Details |
| A49629 | 35685554 | Int J Clin Pract | The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Association of Intestinal Permeability with Disease Severity and Treatment Outcomes. | 2022 | Details |
| A49646 | 35681289 | Foods | Non-Alcoholic Components in Huangjiu as Potential Factors Regulating the Intestinal Barrier and Gut Microbiota in Mouse Model of Alcoholic Liver Injury. | 2022 | Details |
| A49670 | 35675435 | Sci Transl Med | Risk assessment with gut microbiome and metabolite markers in NAFLD development. | 2022 | Details |
| A49708 | 35662935 | Front Nutr | Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis. | 2022 | Details |
| A49732 | 35655096 | Acta Pharmacol Sin | Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity. | 2022 | Details |
| A49752 | 35647690 | Microbiol Spectr | Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. | 2022 | Details |
| A49755 | 35646285 | World J Gastrointest Oncol | Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. | 2022 | Details |
| A49787 | 35637160 | J Gastroenterol Hepatol | Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study. | 2022 | Details |
| A49798 | 35634707 | Gut Microbes | Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis. | 2022 | Details |
| A49800 | 35634340 | Front Immunol | The Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment. | 2022 | Details |
| A49802 | 35633911 | World J Gastroenterol | Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice. | 2022 | Details |
| A49809 | 35630624 | Molecules | Hepatoprotective Effects of Ixeris chinensis on Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice: An Integrated Gut Microbiota and Metabolomic Analysis. | 2022 | Details |
| A49812 | 35629938 | Metabolites | Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability. | 2022 | Details |
| A49829 | 35625757 | Biomedicines | Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. | 2022 | Details |
| A49843 | 35624084 | J Gastroenterol Hepatol | Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A49844 | 35623903 | Phytother Res | Zingiberaceae plants/curcumin consumption and multiple health outcomes: An umbrella review of systematic reviews and meta-analyses of randomized controlled trials in humans. | 2022 | Details |
| A49861 | 35616069 | Food Funct | Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis. | 2022 | Details |
| A49894 | 35605722 | Mol Cell Endocrinol | Recent advances on FXR-targeting therapeutics. | 2022 | Details |
| A49907 | 35600209 | Can J Gastroenterol Hepatol | Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. | 2022 | Details |
| A49913 | 35598686 | Gene | Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A49925 | 35592528 | Oxid Med Cell Longev | Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota. | 2022 | Details |
| A49953 | 35584453 | Braz J Med Biol Res | The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. | 2022 | Details |
| A49954 | 35583582 | Chin J Integr Med | Molecular Mechanism of Polysaccharides Extracted from Chinese Medicine Targeting Gut Microbiota for Promoting Health. | 2022 | Details |
| A49955 | 35583480 | J Agric Food Chem | Spermidine Ameliorates Nonalcoholic Steatohepatitis through Thyroid Hormone-Responsive Protein Signaling and the Gut Microbiota-Mediated Metabolism of Bile Acids. | 2022 | Details |
| A49984 | 35572477 | Gastroenterology Res | Burden and Predictors of Non-Alcoholic Fatty Liver Disease in a Retrospective Cohort of Patients With Crohn's Disease. | 2022 | Details |
| A49993 | 35568374 | Biochim Biophys Acta Mol Cell Biol Lipids | Implications of microbe-mediated crosstalk in the gut: Impact on metabolic diseases. | 2022 | Details |
| A49996 | 35568098 | J Nutr Biochem | Indole supplementation ameliorates MCD-induced NASH in mice. | 2022 | Details |
| A50000 | 35566749 | J Clin Med | Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease. | 2022 | Details |
| A50006 | 35565740 | Nutrients | A Low Glycemic Index Mediterranean Diet Combined with Aerobic Physical Activity Rearranges the Gut Microbiota Signature in NAFLD Patients. | 2022 | Details |
| A50007 | 35565666 | Nutrients | Myristica fragrans Extract Regulates Gut Microbes and Metabolites to Attenuate Hepatic Inflammation and Lipid Metabolism Disorders via the AhR-FAS and NF-κB Signaling Pathways in Mice with Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50021 | 35561146 | Hepatology | Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD. | 2022 | Details |
| A50025 | 35559337 | Front Med (Lausanne) | The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study. | 2022 | Details |
| A50039 | 35551031 | Food Chem | A designed self-microemulsion delivery system for dihydromyricetin and its dietary intervention effect on high-fat-diet fed mice. | 2022 | Details |
| A50056 | 35543143 | Food Funct | Co-interventions with Clostridium butyricum and soluble dietary fiber targeting the gut microbiota improve MAFLD via the Acly/Nrf2/NF-κB signaling pathway. | 2022 | Details |
| A50088 | 35531719 | Zhongguo Zhong Yao Za Zhi | [Mechanism of Tibetan medicine Ershiwuwei Songshi Pills in regulating intestinal flora and improving non-alcoholic steatohepatitis]. | 2022 | Details |
| A50089 | 35531697 | Zhongguo Zhong Yao Za Zhi | [Gynostemma pentaphyllum saponins alleviate non-alcoholic fatty liver disease in rats by regulating intestinal flora and short-chain fatty acid metabolism]. | 2022 | Details |
| A50092 | 35531334 | Front Cell Infect Microbiol | Yiqi-Bushen-Tiaozhi Recipe Attenuated High-Fat and High-Fructose Diet Induced Nonalcoholic Steatohepatitis in Mice via Gut Microbiota. | 2022 | Details |
| A50094 | 35529918 | Evid Based Complement Alternat Med | Efficacy and Mechanism of Mallotus furetianus Müll. Arg. Extract on Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50110 | 35522866 | Wiad Lek | FEATURES OF INTESTINAL MICROBIOTA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: EFFECTS ON MARKERS OF INFLAMMATION AND HEPATIC STEATOSIS. | 2022 | Details |
| A50157 | 35500802 | J Ethnopharmacol | Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. | 2022 | Details |
| A50160 | 35499800 | Biol Trace Elem Res | Selenium-Enriched Probiotic Alleviates Western Diet-Induced Non-alcoholic Fatty Liver Disease in Rats via Modulation of Autophagy Through AMPK/SIRT-1 Pathway. | 2022 | Details |
| A50198 | 35479741 | Front Nutr | Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. | 2022 | Details |
| A50261 | 35450873 | BMJ Case Rep | Case of GPD1 deficiency causing hypertriglyceridaemia and non-alcoholic steatohepatitis. | 2022 | Details |
| A50292 | 35442322 | Arq Gastroenterol | PROBIOTIC, PREBIOTIC OR SYMBIOTIC SUPPLEMENTATION IMPACTS ON INTESTINAL MICROBIOTA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW. | 2022 | Details |
| A50296 | 35440769 | J Antibiot (Tokyo) | Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice. | 2022 | Details |
| A50298 | 35439567 | J Hepatol | Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. | 2022 | Details |
| A50299 | 35439472 | Chem Biol Interact | Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis. | 2022 | Details |
| A50304 | 35437952 | EMBO Mol Med | When fat meets the gut-focus on intestinal lipid handling in metabolic health and disease. | 2022 | Details |
| A50348 | 35421921 | BMC Microbiol | Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. | 2022 | Details |
| A50366 | 35416649 | J Agric Food Chem | Pterostilbene and Its Derivative 3'-Hydroxypterostilbene Ameliorated Nonalcoholic Fatty Liver Disease Through Synergistic Modulation of the Gut Microbiota and SIRT1/AMPK Signaling Pathway. | 2022 | Details |
| A50411 | 35400330 | Endocr Metab Immune Disord Drug Targets | Literature Review on the Use of Herbal Extracts in the Treatment of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50428 | 35396090 | J Pediatr Surg | The preventive effect of recombinant human hepatocyte growth factor for hepatic steatosis in a rat model of short bowel syndrome. | 2022 | Details |
| A50442 | 35390440 | Food Chem Toxicol | Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice. | 2022 | Details |
| A50478 | 35370963 | Front Endocrinol (Lausanne) | The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders. | 2022 | Details |
| A50514 | 35356532 | Front Cell Infect Microbiol | Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids. | 2022 | Details |
| A50526 | 35354069 | Cell Metab | Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. | 2022 | Details |
| A50539 | 35348949 | AAPS PharmSciTech | Development, Characterization, and Investigation of In Vivo Targeted Delivery Efficacy of Luteolin-Loaded, Eudragit S100-Coated mPEG-PLGA Nanoparticles. | 2022 | Details |
| A50576 | 35334784 | Nutrients | Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. | 2022 | Details |
| A50599 | 35328587 | Int J Mol Sci | Usefulness of Probiotics in the Management of NAFLD: Evidence and Involved Mechanisms of Action from Preclinical and Human Models. | 2022 | Details |
| A50610 | 35327326 | Biomedicines | The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. | 2022 | Details |
| A50620 | 35324083 | Chem Biodivers | Effect of Jiangan-Jiangzhi Pill on Gut Microbiota and Chronic Inflammatory Response in Rats with Non-Alcoholic Fatty Liver. | 2022 | Details |
| A50663 | 35308892 | Metabol Open | Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives. | 2022 | Details |
| A50665 | 35308549 | Front Med (Lausanne) | Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis. | 2022 | Details |
| A50667 | 35308229 | Front Pharmacol | Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. | 2022 | Details |
| A50679 | 35305348 | Biomed Pharmacother | Jiangzhi granule attenuates non-alcoholic steatohepatitis through modulating bile acid in mice fed high-fat vitamin D deficiency diet. | 2022 | Details |
| A50682 | 35304191 | Mol Cell Endocrinol | Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. | 2022 | Details |
| A50702 | 35294774 | Eur J Clin Invest | The role of microbiota in nonalcoholic fatty liver disease. | 2022 | Details |
| A50717 | 35288522 | Am J Gastroenterol | Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50737 | 35283218 | Mol Cell Endocrinol | Discovery of farnesoid X receptor and its role in bile acid metabolism. | 2022 | Details |